Clinical Study

A Phase III Trial Evaluating Both Erlotinib And Chemoradiation As Adjuvant Treatment For Patients With Resected Head Of Pancreas Adenocarcinoma

Posted Date: May 15, 2019

  • Investigator: Kevin Redmond
  • Specialties:
  • Type of Study: Drug

Gemcitabine is standard treatment for patients with pancreatic cancer that was removed by surgery. In this study, participants will get either gemcitabine alone or gemcitabine combined with erlotinib. The use of erlotinib to prevent the recurrence of pancreatic cancer after surgery is investigationa

Criteria:

Eligible Patients Must Have Pancreatic Cancer That Was Removed By Surgery. Eligibility Requires Ther

Keywords:

Gastric Cancer, Gi Cancer, Pancreatic Adenocarc, Pancreatic Cancer, R0848

For More Information:

Uc Cancer Institute
513-584-7698
kastla@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.